Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Dr. Peters, Peter Bader, Ulrike Pötschger, M. Akif Yesilipek, Herbert Pichler, Franco Locatelli, Raquel Staciuk, Adriana Balduzzi, Gergely Krivan, Marianne Ifversen, Cristina Díaz De Heredia, Marc Bierings, Jacek Wachowiak, Jean-Hugues Dalle

Blood (2023) 142 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2023-185870

Published: 2023

Journal Articles

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Blood (2023) 142 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2023-177715

Published: 2023

Journal Articles

Longitudinal Assessment of Pubertal Attainment and Testicular Function Following Pediatric Hematopoietic Stem Cell Transplantation: The Role of the Conditioning Regimen

Alessandro Cattoni, Maria Laura Nicolosi, Giulia Capitoli, Alberto Gadda, Silvia Molinari, Louka Sotiri, Andrea Buonsante, Simona Orlandi, Francesca Vendemini, Giorgio Ottaviano, Alberto Gaiero, Graziella Fichera, Andrea Biondi, Adriana Balduzzi

Blood (2023) 142 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2023-190800

Published: 2023

Journal Articles

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Krzysztof Kalwak, Peter Bader, Jean-Hugues Dalle, Petr Sedlacek, Jochen Buechner, Marianne Ifversen, Peter Svec, Jerry Stein, Tayfun Güngör, Jacek Toporski, Cristina Diaz De Heredia, Marc Bierings, Roland Meisel, Marc Ansari, Adriana Balduzzi, Ulrike Poetschger, Dr. Peters, Franco Locatelli

Blood (2023) 142 (Supplement 1): 232.

https://doi.org/10.1182/blood-2023-180728

Published: 2023

Journal Articles

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2023-179306

Published: 2023

Journal Articles

Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study

Blood (2023) 142 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2023-187587

Published: 2023

Journal Articles

Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience

Marta Castelli, Maria Caterina Mico', Anna Grassi, Alessandra Algarotti, Maria Chiara Finazzi, Benedetta Rambaldi, Cristian Meli, Giuliana Rizzuto, Chiara Pavoni, Francesca Vendemini, Marta Verna, Sonia Bonanomi, Adriana Balduzzi, Andrea Biondi, Alessandro Rambaldi, Giacomo Gotti

Blood (2023) 142 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2023-180917

Published: 2023

Journal Articles

Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials

Anita Lawitschka, Jean-Hugues Dalle, Ulrike Pötschger, Helga Arnardottir, Petr Sedlacek, Jochen Büchner, Marianne Ifversen, Peter Svec, Jerry Stein, Tayfun Güngör, Jacek Toporski, Cristina Díaz De Heredia, Marc Bierings, Roland Meisel, Marc Ansari, Adriana Balduzzi, Franco Locatelli, Christina Peters, Peter Bader

Blood (2023) 142 (Supplement 1): 110.

https://doi.org/10.1182/blood-2023-186850

Published: 2023

Journal Articles

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood (2023) 142 (10): 865–877.

https://doi.org/10.1182/blood.2023020578

Published: 2023

Includes: Supplemental data

Journal Articles

Treosulfan Therapeutic Drug Monitoring: Optimizing Conditioning Therapy in Pediatric Hematopoietic Stem Cell Transplantation

Francesco Delle Cave, Simona De Gregori, Sonia Bonanomi, Adriana Balduzzi, Natalia Maximova, Marco Rabusin, Maria Ester Bernardo, Sabrina Basso, Giovanna Giorgiani, Lauren Marguerite Kelly, Marco Zecca

Blood (2022) 140 (Supplement 1): 12854–12855.

https://doi.org/10.1182/blood-2022-164829

Published: 2022

Journal Articles

Long-Term Data Confirm the Superiority of Total Body Irradiation-Containing Conditioning Regimen in Comparison to a Chemotherapy-Based Preparation in Children with Acute Lymphoblastic Leukemia Above the Age of 4 Years Given an Unmanipulated Allograft. Results of the Forum Randomized Clinical Trial

Franco Locatelli, Peter Bader, Jean-Hugues Dalle, Ulrike Poetschger, Herbert Pichler, Petr Sedlacek, Jochen Büchner, Peter J. Shaw, Marianne Ifversen, Raquel Staciuk, Kim Vettenranta, Adriana Balduzzi, Christina Peters

Blood (2022) 140 (Supplement 1): 4865–4867.

https://doi.org/10.1182/blood-2022-166048

Published: 2022

Journal Articles

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Blood (2022) 140 (Supplement 1): 10339–10340.

https://doi.org/10.1182/blood-2022-166788

Published: 2022

Journal Articles

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Blood (2022) 140 (Supplement 1): 4568–4569.

https://doi.org/10.1182/blood-2022-165448

Published: 2022

Journal Articles

Relapse Is the Most Common Treatment Failure Post HSCT in Children with ALL below 4 Years of Age Given a Chemo-Based Conditioning Regimen. Results from the Prospective Multinational Forum-Trial

Christina Peters, Ulrike Poetschger, Jean-Hugues Dalle, Akif Yesilipek, Jerry Stein, Herbert Pichler, Adriana Balduzzi, Franco Locatelli, Petr Sedlacek, Jacek Wachowiak, Tayfun Güngör, Marianne Ifversen, Marleen Renard, Tony H Truong, Raquel Staciuk, Peter J. Shaw, Gergely Kriván, Jochen Büchner, Peter Bader

Blood (2022) 140 (Supplement 1): 897–899.

https://doi.org/10.1182/blood-2022-168609

Published: 2022

Journal Articles

Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study

Jean-Hugues Dalle, Peter Bader, Akif Yesilipek, Franco Locatelli, Julia Palma, Jacek Wachowiak, Herbert Pichler, Marianne Ifversen, Gergely Kriván, Jochen Buechner, Cristina Díaz-de-Heredia, Marc Bierings, Raquel Staciuk, Tayfun Gungor, Jacek Toporski, Adriana Balduzzi, Ulrike Poetschger, Christina Peters, Petr Sedlacek

Blood (2022) 140 (Supplement 1): 903–905.

https://doi.org/10.1182/blood-2022-164735

Published: 2022

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Blood (2021) 138 (Supplement 1): 472.

https://doi.org/10.1182/blood-2021-148703

Published: 2021

Journal Articles

Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study

Blood (2021) 138 (Supplement 1): 2862.

https://doi.org/10.1182/blood-2021-145858

Published: 2021

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141236

Published: 2020

Journal Articles

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2019) 134 (Supplement_1): 200.

https://doi.org/10.1182/blood-2019-125894

Published: 2019

Journal Articles

Unrelated donor vs HLA-haploidentical α/β T-cell– and B-cell–depleted HSCT in children with acute leukemia

Blood (2018) 132 (24): 2594–2607.

https://doi.org/10.1182/blood-2018-07-861575

Published: 2018

Includes: Supplemental data

NARROW

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Longitudinal Assessment of Pubertal Attainment and Testicular Function Following Pediatric Hematopoietic Stem Cell Transplantation: The Role of the Conditioning Regimen

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study

Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience

Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Treosulfan Therapeutic Drug Monitoring: Optimizing Conditioning Therapy in Pediatric Hematopoietic Stem Cell Transplantation

Long-Term Data Confirm the Superiority of Total Body Irradiation-Containing Conditioning Regimen in Comparison to a Chemotherapy-Based Preparation in Children with Acute Lymphoblastic Leukemia Above the Age of 4 Years Given an Unmanipulated Allograft. Results of the Forum Randomized Clinical Trial

Carcik-CD19 Cells Expand In Vivo Toward a CD8 + Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Relapse Is the Most Common Treatment Failure Post HSCT in Children with ALL below 4 Years of Age Given a Chemo-Based Conditioning Regimen. Results from the Prospective Multinational Forum-Trial

Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study

Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Unrelated donor vs HLA-haploidentical α/β T-cell– and B-cell–depleted HSCT in children with acute leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only